Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

BACKGROUND: Eribulin mesilate (eribulin), a non-taxane microtubule dynamics inhibitor, has shown trends towards greater overall survival (OS) compared with progression-free survival in late-stage metastatic breast cancer patients in the clinic. This finding suggests that eribulin may have additional...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, T, Ozawa, Y, Kimura, T, Sato, Y, Kuznetsov, G, Xu, S, Uesugi, M, Agoulnik, S, Taylor, N, Funahashi, Y, Matsui, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960630/
https://www.ncbi.nlm.nih.gov/pubmed/24569463
http://dx.doi.org/10.1038/bjc.2014.80

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960630/
https://www.ncbi.nlm.nih.gov/pubmed/24569463
http://dx.doi.org/10.1038/bjc.2014.80

Ejemplares similares